Tunable nanocomplexes for delivery of plasmid DNA into human and vertebrate primary cells

Technology #d-1451

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Huanyu Dou
External Link (elpaso.ttuhsc.edu)
Managed By
Cameron Smith
Licensing Associate 806-834-6822
Patent Protection

Provisional Patent Application Filed

Historically, poly(D,L-lactide-co-plycolide) (PLGA) complexes with polyethylenimine (PEI) coated surfaces have been used  as a DNA delivery mechanism in gene therapy. This allows for a complex that has relatively low cytotoxicity, binds DNA, and has a cationic surface to allow for easy entry into the target cell. However, these complexes still maintain an amount of cytotoxicity due to the nature of PEI. Smaller PEI molecules have low cytotoxic effects, but then have almost no transfection ability. The present invention uses lower molecular weight PEI along with an attached glycidyl hexadecyl ether to ultimately lower cytotoxic effects of the PEI-PLGA complex while increasing transfection ability. These PEI-PLGA complexes are successfully able to transfect genes into target cells, specifically macrophages, with decreased cytotoxicity and increased transfection ability.

Features, Benefits & Advantages:

  • Decreased cytotoxicity in gene therapy complexes
  • Increased transfection ability in nanocomplexes¬†

Stage of Development:

  • Efficacy testing has been completed with positive results.¬†

Intellectual Property:

  • A provisional patent application was filed 11/29/2017.

Primary Investigators:

  • Huanyu Dou, MD, Texas Tech University Health Sciences Center, El Paso, TX.